en · de · es · fr · pt
thymosin-alpha-1-notes.peptides6908.com › Faq › Background And Molecular Identity — Background and Details

Background And Molecular Identity — Background and Details

By Editorial Desk · published 2025-10-30 · last reviewed 2025-12-07 · Faq

This is a working overview of Immune modulation, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2025-12-07 and is reviewed periodically as new material appears.

Background and Molecular Identity

Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.

The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.

Molecular Structure and Biological Background

Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.

Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.

Thymosin-alpha-1 at a glance

PropertyValueNotes
Molecular massAbout 3.1 kDa28 residues, N-terminally acetylated
AppearanceWhite to off-white powderLyophilized solid
SolubilityFreely soluble in waterAlso soluble in aqueous buffers
Storage temperature2 to 8 °CProtect from light and moisture
Common synonymsThymalfasin; Tα1Same peptide sequence

Background and Mechanism of Action

Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.

Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.

Related pages on this site

分子身份与天然来源

20世纪70年代,研究者从胸腺提取物中纯化出多种小肽,Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤,产量低且成分复杂。随着固相肽合成技术成熟,实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上,并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。

市售的胸腺素α1通常以冻干粉形式提供,溶解后用于注射。其氨基酸组成包括多个酸性残基,因此在中性pH下带负电荷。该肽可溶于水和生理盐水,但在有机溶剂中溶解度有限。储存条件通常为冻干状态下负20摄氏度,溶解后需冷藏并避免反复冻融。常见的同义词包括胸腺肽α1、thymalfasin和Tα1。

Further detail

4-HO-MET binds to various serotonin receptors and is known to act as an agonist of the serotonin 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT1A receptors. It is thought that the hallucinogenic effects of serotonergic psychedelics like 4-HO-MET are mediated by serotonin 5-HT2A receptor activation.

However, Compulsion also said that with this expanded title, the price of the game will be increased from $30 to $60, with those that backed the Kickstarter or purchased the early access versions getting the full game and some of the downloadable content that is planned for free. Compulsion plans to offer a season pass for additional content that will be developed after release, enabled by Gearbox's backing. Compulsion's community manager Nadia Hadjas said that neither Microsoft nor Gearbox provided oversight on the game, allowing Compulsion to develop the title based on their own goals and the community's feedback. In May 2018, the Australian Classification Board had refused classification for We Happy Few, identifying that gameplay mechanics around the use of Joy pills was problematic, which would prevent the game from being sold in Australia. The Board stated in their refusal that because "the game's drug-use mechanic making game progression less difficult constitutes an incentive or reward for drug-use and therefore, the game exceeds the R18+ classification that states, 'drug use related to incentives and rewards is not permitted'". Compulsion Games said that it was working with the Board to challenge their ruling and make the game appropriate to be rated, stating that they believe that the use of Joy was part of the game's themes, "It's a society that is forcing its citizens to take Joy, and the whole point of the game is to reject this programming and fight back", and compared this theme to that of Aldous Huxley's Brave New World and Terry Gilliam's Brazil.

The spleen is the organ which removes damaged or misshapen red blood cells from the circulation. In thalassemia, this can lead to the spleen becoming enlarged, a condition known as splenomegaly. Slight enlargement of the spleen is not a problem, however if it becomes extreme then surgical removal of the spleen (splenectomy) may be recommended.

Sources: en.wikipedia.org

Supporting material

=== 1970s: Heseltine takes ownership of Haymarket === In 1970, Heseltine turned down the chance to invest £25,000 in the advertising agency Saatchi & Saatchi when it was set up (his former employee Maurice Saatchi said that he had learned a great deal from Heseltine's aggressive techniques of acquiring magazine titles, and from publicity in Campaign magazine), believing wrongly that it was against the code for ministers to make such an investment. Lindsay Masters did invest, but was eventually bought out by the Saatchi brothers; Heseltine later believed that he and Masters together could have made another fortune if they had reinforced one another with large shareholdings in Saatchi and Saatchi. With Heseltine a government minister from June 1970, Haymarket was being run by Masters and Tindall, who had secured another coup by publishing Computing for the British Computing Society. BPC was in financial trouble in 1971, and Heseltine, Masters and Tindall assembled a consortium of County Bank, Charterhouse Development, ICFC and Wren Investments to help buy out BPC's 60% stake for £1m, a very low price given that Haymarket had made over £250,000 the previous year. The consortium took a 40% stake in Haymarket, and loaned the company £820,000, while Heseltine took out a large personal loan at this time to buy both another 20% of Haymarket's shares (the rest of the BPC shareholding, bringing Heseltine's own shareholding to just under 50%).

== Physiological mechanism of action == β-Amanitin is able to travel through the bloodstream to reach the organs in the body. While it damages all organs, damage to the liver and heart result in fatalities. At the molecular level amanitin toxins cause damage to cells of these organs. The toxins may also cause disruptions in the plasma membranes resulting in organelles that are normally in the cytoplasm to be found in the extracellular matrix. beta-Amanitin is also an inhibitor of eukaryotic RNA polymerase II and RNA polymerase III, and as a result, mammalian protein synthesis. It has not been found to inhibit RNA polymerase I or bacterial RNA polymerase. Because it inactivates the RNA polymerases, the liver is unable to repair the damage that beta-Amanitin causes and the cells of the liver disintegrate and the liver dissolves.

Trump called on House and Senate Republicans to kill the bill, arguing it would hurt his and the Republican Party's reelection campaigns and deny them the ability to run on immigration as a campaign issue. Harris criticized Trump for his opposition to the bill on the campaign trail, and promised to sign the bill into law as president.

Sources: en.wikipedia.org

Supporting material

=== Nosocomial infections === Clostridioides difficile, gram-positive bacteria species that inhabits the gut of mammals, exemplifies one type of bacteria that is a major cause of death by nosocomial infections. When symbiotic gut flora populations are disrupted (e.g., by antibiotics), one becomes more vulnerable to pathogens. The rapid evolution of antibiotic resistance places an enormous selective pressure on the advantageous alleles of resistance passed down to future generations. The Red Queen hypothesis shows that the evolutionary arms race between pathogenic bacteria and humans is a constant battle for evolutionary advantages in outcompeting each other. The evolutionary arms race between the rapidly evolving virulence factors of the bacteria and the treatment practices of modern medicine requires evolutionary biologists to understand the mechanisms of resistance in these pathogenic bacteria, especially considering the growing number of infected hospitalized patients. The evolved virulence factors pose a threat to patients in hospitals, who are immunocompromised from illness or antibiotic treatment. Virulence factors are the characteristics that the evolved bacteria have developed to increase pathogenicity. One of the virulence factors of C. difficile that largely constitutes its resistance to antibiotics is its toxins: enterotoxin TcdA and cytotoxin TcdB. Toxins produce spores that are difficult to inactivate and remove from the environment. This is especially true in hospitals where an infected patient's room may contain spores for up to 20 weeks.

=== Criminal justice === As attorney general, Schmitt supported an effort in the Missouri legislature to increase the number of police officers in St. Louis City by lifting the residency requirement for police officers.

=== Pathogens === E-liquid used in e-cigarettes has been found to be contaminated with fungi and bacteria. Nicotine-containing e-liquids are extracted from tobacco that may contain impurities. Tobacco-specific impurities such as cotinine, nicotine-N'-oxides (cis and trans isomers), and beta-nornicotyrine are believed to be the result of bacterial action or oxidation during the extraction of nicotine from tobacco.

== Function == The MT-TD gene encodes for a small transfer RNA (human mitochondrial map position 7518–7585) that transfers the amino acid aspartic acid to a growing polypeptide chain at the ribosome site of protein synthesis during translation.

Sources: en.wikipedia.org

Frequently asked questions

What is thymosin alpha-1?

It is a 28-residue synthetic peptide studied as an immune-modulating agent and approved as a drug in some countries. The sequence matches a naturally occurring fragment isolated from thymus tissue. It is not a hormone in the endocrine sense.

Where does the name come from?

The name traces back to thymosin fraction 5, a crude thymus extract examined in the 1970s. Individual peptides in that mixture were labeled with Greek letters, and alpha-1 was one of them. The international nonproprietary name thymalfasin was assigned later.

Is it the same as thymosin beta-4?

No. Thymosin beta-4 contains 43 residues and binds actin, while thymosin alpha-1 contains 28 residues and acts on immune cells. The two sit in a historical naming group but share no sequence similarity, and they are not substitutes for one another.

Is thymosin alpha-1 a naturally occurring hormone?

It corresponds to a fragment of the larger protein prothymosin alpha, which is present in many tissues. The isolated 28-amino-acid peptide was originally obtained from thymus preparations, and the pharmaceutical product is synthesized rather than extracted. The term therefore describes both a natural fragment and a manufactured drug substance.

Network